NAD+ safety splits between trials and preparations

No flushing in Conze’s NR trial

In the oral record for NAD+ side effects, the eight-week NR trial found no flushing and no significant adverse-event difference from placebo at its tested amounts. The 60-day NMN trial identified no safety issue in the tested groups. These are useful findings about the people and periods studied.

I trust those narrow descriptions more than the bare sentence ‘NAD+ is safe’. NAD+ already being present in cells does not settle the safety of a particular intervention. And daily administration during a short trial does not settle daily use for years.

An injection brings the preparation into the question

A compounded NAD+ injection or IV drip has no FDA approval. The current research record includes a Class I recall of a compounded NAD+ injection for elevated bacterial endotoxin. Endotoxin is material from bacteria that can cause harmful reactions; the preparation itself can introduce a safety problem before efficacy is even addressed.

Infusion reports also describe nausea, flushing, abdominal discomfort and chest pressure, particularly with faster delivery. Reported symptoms resolved with completion of the infusion. These reports do not provide a reliable duration for side effects in every person or establish long-term safety.

The manufacturing history gives the safety question an additional layer, even with a reassuring oral trial. I cannot make one route's tolerability stand in for another route's preparation or administration.

Melanoma supplies the objection to ‘more’

Melanoma cells in laboratory work increased their NAD+ rebuilding machinery; blocking it depleted NAD+ and ATP, and improved survival in mice carrying tumors. The review of NAD+ deficits and cancer describes the other side of a context-dependent relationship.

The cancer result is the strongest objection I can see to a universal replenishment verdict. The experiments concern cell lines and tumor-bearing mice. The concern about supplementation in cancer remains theoretical in people in this record. My caution concerns the enlarged conclusion about benefit.

NMN’s muscle effect left weight unchanged

In the NMN trial in prediabetic, postmenopausal women, body composition and weight did not change even though muscle insulin sensitivity improved. The cited human trials do not demonstrate a weight-loss benefit.

Improved glucose handling by a muscle is a narrower observation than a change on a scale. It deserves to remain one.

Fertility and patches are still unanswered here

The metabolic human trial and heart-failure study did not measure fertility outcomes. No human fertility benefit is established by this set of papers.

NAD+ patches, nasal sprays and sublingual preparations have little controlled evidence in the current research record. The much larger oral precursor record cannot prove that a patch delivers NAD+ effectively or improves health. A patch still needs controlled delivery and outcome data of its own.

Energy anecdotes leave the cause untested

Questions about more energy or less brain fog after NAD+ treatments remain questions. Personal reports are anecdotal accounts, not clinical evidence; they can describe an experience without identifying its cause. No dose or schedule follows from them.

The energy anecdote hasn’t earned my confidence as an explanation. The 2025 review leaves human efficacy for major clinical outcomes limited despite reliable blood NAD+ increases. That is the unresolved part of the safety-and-benefit bargain.